3Francis PA, Rigas JR, Kris MG, et al. Phase Ⅱ trial of docetaxel in patients in with stage Ⅲ and Ⅳ non-small cell lung cancer. J Clin Oncol,1994, 12: 1232-1237.
4Hainsworth JD,Burris Ⅲ HA, Greco FA. Weekly Administration of Docetaxel (Taxotere): summary of clinical data. Semin Oncol,1999,26( Suppl 10) : 19-24.
5Fossella FV, Lee JS, Murphy WK, et al. Phase Ⅱ study of docetaxel for recurrent or metastatic non small cell lung cancer. J Clin 0ncol, 1994, 12: 1238-1244.
6Fossella FV, Lee JS, Berilh J, et al. Summary of phase Ⅱ data of docetaxel(Taxotere), an active agent in the first and second line treatment of advanced non small cell lung cancer. Semin Oneol,1995, 22(2 Suppl 4) :22-29.
7Belani CP. Single agents in the second line treatment of non small cell lung cancer. Semin 0neol,1998, 25(3 Suppl 8) : 10-14.
8Ravdin PM, Bun'is HA, Cook G, et al. Phase Ⅱ trial of docetaxel inadvanced anthracicline-resistant or anthracenedione-resistant breast cancer. J Clin 0ncol,1995, 13:2879-2885.
9Kubota K, Watanabe K, Kunitoh H,et al. Phase Ⅲ randomized trial of decetaxel plus cisplatin versus vindesine plus cispaltin in patients with stage Ⅳ non small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol, 2004, 22:354-261.
10Fossella F, Pereira JR, von Pawel JV, et al. Bandomezed,multinational, phase Ⅲ study of decetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non small cell lungcancer: the TAX 326 study group. J Clin Oncol,2003,21:3016-3024.
